Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195863 | 0.92 | PARP1 (0.44) | PARP1PRMT5ROCK2GRIN2BPDK1 | |
| SCHEMBL12422788 | 0.92 | PARP1 (0.44) | PARP1PRMT5ROCK2GRIN2BPDK1 | |
| SCHEMBL934253 | 0.90 | PARP1 (0.43) | PARP1PRMT5TMEM97SIGMAR1ROCK2 | |
| SCHEMBL934303 | 0.88 | PARP1 (0.43) | PARP1PRMT5ROCK2GRIN2BPDK1 | |
| SCHEMBL12509303 | 0.84 | PARP1 (0.46) | PARP1PRMT5ROCK2GRIN2BPDK1 | |
| SCHEMBL12509783 | 0.84 | PARP1 (0.46) | PARP1PRMT5ROCK2GRIN2BPDK1 | |
| SCHEMBL1041817 | 0.83 | PARP1 (0.45) | PARP1PRMT5ROCK2GRIN2BPDK1 | |
| SCHEMBL12509649 | 0.82 | PRMT5 (0.44) | PARP1PRMT5TMEM97SIGMAR1BACE1 | |
| SCHEMBL2775036 | 0.81 | PARP1 (0.45) | PARP1PRMT5ROCK2GRIN2BPDK1 | |
| SCHEMBL2197306 | 0.80 | TMEM97 (0.41) | TMEM97SIGMAR1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | PARP1 3389/4885PRMT5 2258/4885TMEM97 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.